Molecular mechanisms of metastasis in prostate cancer

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 57-67

  Clarke, Noel W ^a   Hart, Claire A ^a   Brown, Mick D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BETA CATENIN; BETA1 INTEGRIN; BETA4 INTEGRIN; CADHERIN; CATENIN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; LAMININ; LIPID; MESSENGER RNA; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; RAS PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STROMAL CELL DERIVED FACTOR 1;

BONE MARROW CELL; BONE MARROW STROMA; BONE METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL MOTION; CELL PROLIFERATION; DNA BINDING; DOWN REGULATION; DRUG ACTIVITY; ENDOTHELIUM; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; MORBIDITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLASMA CLEARANCE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STROMA; BONE TUMOR; MALE; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

BONE NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CHEMOKINES; HUMANS; LIPIDS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 69249244442     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.29     Document Type: Review

References (93)

1. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986; 46: 1-7.
2. Clarke N, Brown M. Molecular Mechanisms of Metastasis in Prostate Cancer. In: Kirby RS, Partin AW, Feneley M, Parsons JK, editors. Prostate Cancer: Principles And Practice. London&New York: Taylor and Francis; 2006. p383-400.
3. Birchmeier W, Behrens J. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1994; 1198: 11-26.
4. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85.
5. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992; 52: 2916-22.
6. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19.
7. Takeichi M. Cadherin cell adhesion receptors as a morphoge netic regulator. Science 1991; 251: 1451-5.
8. Näthke IS, Hinck L, Swedlow JR, Papkoff J, Nelson WJ. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol 1994; 125: 1341-52.
9. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-3.
10. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996; 148: 1375-80.
11. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, et al Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-33.
12. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52: 5104-9.
13. McWilliam LJ, Knox WF, Hill C, et al. E-Cadherin expression fails to predict progression and survival in prostate cancer. J Urol 1996; 155: 516A.
14. Bryden AAG, Freemont AJ, Clarke NW, George NJ. Paradoxical expression of E-cadherin in prostatic bone metastases. BJU Int 1999; 84: 1032-4.
15. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, et al. Cadherin dysfunction in a human cancer cell line: Possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res 1992; 52: 5770-4.
16. Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y. E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: Correlation with tumour invasion. Br J Cancer 1999; 79: 1879-83.
17. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, et al. Coordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997; 33: 263-71.
18. Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997; 74: 374-7.
19. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-3.
20. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995; 14: 219-28.
21. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992; 11: 353-75.
22. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 1994; 19: 232-7.
23. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-72.
24. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993; 53: 4493-8.
25. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, et al. Differential inhibition of invasion and proliferation by bisphosphonates: Anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol 2004; 46: 389-401.
26. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
27. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, et al. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 2002; 86: 1136-42.
28. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 2003; 189: 117-28.
29. Johnston SR. Farnesyl transferase inhibitors: A novel targeted therapy for cancer. Lancet Oncol 2001; 2: 18-26.
30. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126-35.
31. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-74.
32. Giniger E. How do Rho family GTPases direct axon growth and guidance? A proposal relating signaling pathways to growth cone mechanics. Differentiation 2002; 70: 385-96.
33. Khafagy R, Stephens T, Hart C, et al. In vitro effects of the prenyl transferase inhibitor AZD3409 on prostate cancer epithelial cells. J Clin Oncol 2004; 22: 442S.
34. Heung YM, Walsh K, Sriprasad S, Mulvin D, Sherwood RA. The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int 2000; 85: 65-9.
35. Straub B, Müller M, Krause H, Schrader M, Goessl C, et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction. Urology 2001; 58: 815-20.
36. Eschwège P, Dumas F, Blanchet P, Le Maire V, Benoit G, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995; 346: 1528-30.
37. Price DK, Clontz DR, Woodard WL 3rd, Kaufman JS, Daniels JM, et al Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay. Urology 1998; 52: 261-6; discussion 266-7.
38. Siddiqua A, Chendil D, Rowland R, Meigooni AS, Kudrimoti M, et al. Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer. Urology 2002; 60: 270-5.
39. Hart CA, Brown M, Bagley S, Sharrard M, Clarke NW. Invasive characteristics of human prostatic epithelial cells: Understanding the metastatic process. Br J Cancer 2005; 92: 503-12.
40. McIntyre IG, Bhatt RI, Clarke NW. Isolation of epithelial cells from blood and bone marrow of prostate cancer patients. Prostate Cancer Prostatic Dis 2002; 5: S21.
41. Orr FW, Sanchez-Sweatman OH, Kostenuik P, Singh G. Tumor-bone interactions in skeletal metastasis. Clin Orthop Relat Res 1995; 312: 19-33.
42. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998; 90: 118-23.
43. Tang DG, Chen YQ, Newman PJ, Shi L, Gao X, et al. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 1993; 268: 22883-94.
44. Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, et al. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: Close association with advanced disease stage and lymph node metastasis. Hum Pathol 1999; 30: 458-66.
45. Voura EB, Sandig M, Siu CH. Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech 1998; 43: 265-75.
46. Hartstein ME, Grove AS Jr, Woog JJ. The role of the integrin family of adhesion molecules in the development of tumors metastatic to the orbit. Ophthal Plast Reconstr Surg 1997; 13: 227-38.
47. Rabinovitz I, Nagle RB, Cress AE. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migra tory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 1995; 13: 481-91.
48. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998; 51: 191-200.
49. Trikha M, Raso E, Cai Y, Fazakas Z, Paku S, et al. Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 1998; 35: 185-92.
50. Lang SH, Clarke NW, George NJ, Allen TD, Testa NG. Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 1998; 34: 203-13.
51. Lang SH, Clarke NW, George NJ, Testa NG. Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha 2 beta 1 integrin. Clin Exp Metastasis 1997; 15: 218-27.
52. Curry FE. Modulation of venular microvessel permeability by calcium influx into endothelial cells. Faseb J 1992; 6: 2456-66.
53. Lewalle JM, Cataldo D, Bajou K, Lambert CA, Foidart JM. Endothelial cell intracellular Ca2+ concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migration. Clin Exp Metastasis 1998; 16: 21-9.
54. 2+ increases upon tumor cell contact and modulates cell-cell adhesion. J Clin Invest 1993; 92: 3017-22.
55. Khafagy R, Stephens T, Hart C, et al. The novel oral protein prenyl transferase inhibitor AZD3409 inhibits prostate epithelial cell proliferation and invasion in vitro, without bone marrow toxicity. Eur Urol Suppl 2005; 4: 54.
56. Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62: 2708-14.
57. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7.
58. Müller A, Homey B, Soto H, Ge N, Catron D, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
59. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-20.
60. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-9.
61. Hamada T, Möhle R, Hesselgesser J, Hoxie J, Nachman RL, et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 1998; 188: 539-48.
62. Aiuti A, Tavian M, Cipponi A, Ficara F, Zappone E, et al. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol 1999; 29: 1823-31.
63. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-8.
64. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425: 307-11.
65. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003; 22: 8093-101.
66. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 2000; 6: 3530-5.
67. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89: 462-73.
68. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550: 79-83.
69. Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H, et al. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 2003; 91: 716-20.
70. Brown MD, Hart CA, Gazi E, Bagley S, Clarke NW. Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br J Cancer 2006; 94: 842-53.
71. Nelson JB. Endothelin inhibition: Novel therapy for prostate cancer. J Urol 2003; 170: S65-7; discussion S67-8.
72. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97: 779-84.
73. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, et al Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663-8.
74. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-9.
75. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999; 53: 1063-9.
76. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83: 360-5.
77. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8.
78. Bryden AA, Islam S, Freemont AJ, Shanks JH, George NJ, et al. Parathyroid hormone-related peptide: Expression in prostate cancer bone metastases. Prostate Cancer Prostatic Dis 2002; 5: 59-62.
79. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-31.
80. Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996; 48: 317-25.
81. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142: 407-15.
82. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, et al Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983; 51: 918-24.
83. Clarke NW, McClure J, George NJR. Morphometric evidence for bone-resorption and replacement in prostate-cancer. Br J Urol 1991; 68: 74-80.
84. Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate-cancer. Eur Urol 1993; 24: 286-90.
85. Cook GB, Watson FR. Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol 1968; 99: 87-96.
86. Galasko CS. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976; 263: 507-8.
87. Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone-resorption in metastatic prostate-cancer. Br J Urol 1992; 69: 64-70.
88. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-3.
89. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-91.
90. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.
91. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
92. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-8.
93. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.